Rift Valley fever virus (RVFV) belongs to the family of Phenuiviridae within the order of Bunyavirales. The virus may cause fatal disease both in livestock and humans, and therefore, is of great economical and public health relevance. In analogy to the influenza virus polymerase complex, the bunyavirus L protein is assumed to bind to and cleave off cap structures of cellular mRNAs to prime viral transcription. However, even though the presence of an endonuclease in the N-terminal domain of the L protein has been demonstrated for several bunyaviruses, there is no evidence for a cap-binding site within the L protein. We solved the structure of a C-terminal 117 amino acid-long domain of the RVFV L protein by Xray crystallography. The overall fold of the domain shows high similarity to influenza virus PB2 cap-binding domain and the putative non-functional cap-binding domain of reptarenaviruses. Upon co-crystallization with m 7 GTP, we detected the cap-analogue bound between two aromatic side chains as it has been described for other cap-binding proteins. We observed weak but specific interaction with m 7 GTP rather than GTP in vitro using isothermal titration calorimetry. The importance of m 7 GTP-binding residues for viral transcription was validated using a RVFV minigenome system. In summary, we provide structural and functional evidence for a cap-binding site located within the L protein of a virus from the Bunyavirales order.
GTP rather than GTP in vitro using isothermal titration calorimetry. The importance of m 7 GTP-binding residues for viral transcription was validated using a RVFV minigenome system. In summary, we provide structural and functional evidence for a cap-binding site located within the L protein of a virus from the Bunyavirales order.
Author summary
Rift Valley fever virus (RVFV) is endemic to sub-Saharan Africa and the Arabian Peninsula and leads to abortions in and death of ruminants. The virus can also be transmitted to humans causing febrile illness up to hemorrhagic fever with the possibility of fatal outcome. As there is currently no human vaccine or specific treatment available and because of the high epidemic potential, WHO has listed RVFV on its R&D Blueprint for urgent development of medical countermeasures. In order to amplify, the virus needs to transcribe and replicate the viral genome inside the cell cytoplasm. For transcription, the virus uses a process called cap-snatching, which is essentially depending on two functions presumed to reside within the large viral L protein: the ability to bind cap-structures and the activity of cleaving them off from cellular mRNA. Both functions could serve as specific and binding mode of the cap. In summary, we present evidence for a cap-binding site located within the L protein of a virus from the Bunyavirales order. This work also provides the basis for the design of specific compounds targeting RVFV cap-binding domain.
Results

Construct design and identification of a small domain in the RVFV L protein C-terminus
A secondary structure based sequence alignment of the C-termini of phlebo-and closely related banyangvirus L proteins was created to identify the region of the L protein, which might contain the potential cap-binding site (S1 Fig). Guided by the information about the structural composition of cap-binding domains from influenza virus PB2 and the putative cap-binding domain of California Academy of Sciences virus (CASV) L protein, we searched for several β-strands interspersed with one to three α-helices. The region between residues 1677 and 2008 of the RVFV L protein was identified as target region. We designed and cloned six different constructs from this area (putative cap-binding domain CBD 1-6) and tested for soluble expression in Escherichia coli. Construct details and expression data are summarized in S2 Fig. Two of the proteins could be solubly expressed (CBD2: residues 1677-1827; and CBD4: residues 1706-1827) but not well purified. Therefore, we designed further constructs (CBD 7-14) based on these soluble candidates and obtained two proteins suitable for crystallization experiments: CBD9 (residues 1719-1827) and CBD13 (residues 1706-1822).
Crystallization and structure determination of a RVFV L protein Cterminal domain
Both CBD9 and CBD13 proteins were crystallized. During the purification process up to 6 mM of m 7 GTP was added, as it significantly reduced precipitation of the protein at low concentrations. Only CBD13 crystals were of good quality. This protein crystallized in space group P2 1 2 1 2 1 with two molecules per asymmetric unit and the structure could be refined to a resolution of 1.5 Å (Fig 1A, S1 Table, PDB ID 6QHG) . Thus, from now on CBD13 will be referred to as RVFV CBD. Except for the N-terminal residues 1706-1707 in chain B clear electron density was observed for the whole structure. RVFV CBD crystallized as a dimer (Fig 1A) , which is not fully symmetric (Fig 1B) , with a buried surface area of~430 Å 2 between the monomers (see also S3 Fig) . The most prominent difference between the monomers is observed between residues 1718 and 1729, which constitute a β-hairpin. This β-hairpin has a slightly different position in both chains (Fig 1B, β-hairpin colored in teal). In solution, the protein appears to be monomeric, as revealed by size-exclusion chromatography (S4 Fig,  buffer composition: 50 mM Na-phosphate, pH 6.5, 150 mM NaCl, 10% (w/v) glycerol). The structure of RVFV CBD consists of a β-sheet formed by seven β-strands, an additional β-hairpin as well as a long α-helix (Fig 1A and 1B) . Overall the structure seems to be very rigid with low B-factors and only the β-hairpin shows some flexibility (Fig 1C) .
Identification and structural configuration of a cap-binding site in RVFV CBD
two aromatic amino acid side chains, F1713 and Y1728 (Fig 2) . Y1728 is located in the β-hairpin (β H2 ) and F1713 in the first β-strand (β 1 ). The phosphate moiety of the cap structure interacts with R1716 side chain, which is extending from the loop between the first β-strand and the β-hairpin. Further contacts with the m 7 GTP involve M1782, interacting with the guanine moiety and ribose of the cap-structure, as well as Q1717, interacting with the guanine moiety (Fig 2B and 2C, S5B Fig, S2 Table) . F1713, Y1728 and Q1717 are chemically conserved among phlebo-and banyangviruses, whereas for M1782 and R1716 the degree of conservation within the chemical class is about 95% and 20%, respectively (Fig 3) . For chain A, some residues from neighboring molecules in the crystal also interact with the tri-phosphate of m 7 GTP. Due to the crystal symmetry, this is not the case for the m 7 GTP of chain B and the electron density for the ligand in chain B is less clear than in chain A (compare Fig 2A and S5A Fig) . In summary, RVFV CBD was crystallized with an m 7 GTP ligand bound between two aromatic side chains. Such an arrangement is found in several cellular and viral cap-binding proteins, as reviewed by Fechter and Brownlee in 2005 [25] .
In vitro interaction studies of RVFV CBD with cap-structures
To verify that this binding pocket is specific for a methylated nucleotide, such as a cap-structure, we performed thermal stability assays using influenza virus PB2 cap-binding domain as a control. Addition of m 7 GTP to influenza virus PB2 cap-binding domain stabilized the protein, resulting in a higher melting temperature (ΔTm = 9˚C in the presence of 10 mM m 7 GTP). We tested thermal stability of RVFV CBD in the presence of m We observed a specific stabilization of RVFV CBD by m 7 GTP as well as m 7 GpppG (ΔTm = 3-4˚C) compared to no or even negative effects on protein stability after addition of GTP or ATP, respectively (Fig 4A) . Isothermal titration calorimetry (ITC) measurements revealed a (Fig 4B) , which is considerably higher than the K D of 1.5 μM reported for m 7 GTP binding to influenza virus PB2 [26] . For GTP the K D is too high to be determined by ITC under the same conditions as used for m 7 GTP (Fig 4B) . Thus, ITC [53] [54] [55] [56] and presented by ESPript (http:// espript.ibcp.fr) [57] . Residue numbers refer to RVFV strain ZH-501 full-length L protein. Secondary structure elements of RVFV ZH-501 according to the RVFV CBD structure are depicted below the sequences. Residues involved in the cap-binding site are labelled with the same color code as used in Fig 2C . 
Functional analysis of mutations of the cap-binding site in the context of the full-length L protein
The RVFV minireplicon system [23] was used to test the effect of mutations in the cap-binding site on the ability of the L protein to transcribe and replicate the viral genome. By using an ambisense minigenome we were able to discriminate between (1) mRNA production, a process depending on the cap-snatching mechanism for priming, and (2) antigenome synthesis, which is independent of a primer. Synthesis of these two RNA species was measured via expression of renilla luciferase ((Ren-Luc)reflecting essentially viral transcription) and quantitative analysis of bands of antigenomic RNA and renilla luciferase mRNA on a northern blot. We know from previous experiments with the Lassa virus replicon system [22, 27, 28] that modification of L protein residues often affects the RNA polymerase function globally, which manifests as partial or complete defect in synthesis of all viral RNA species, i.e. replicative intermediates (antigenome) and mRNA. However, residues selectively important for viral transcription including cap-binding are expected to show a specific phenotype characterized by (i) reduced Ren-Luc signals indicating reduced mRNA synthesis, (ii) wild-type-like antigenome levels in the northern blot indicating functional RNA polymerase and (iii) a reduced mRNA-to-antigenome ratio as calculated from the quantitative northern blot data indicating a specific defect in transcription vs. replication (S3 Table) . We exchanged eight residues of the cap-binding pocket and surrounding areas both for chemically similar and different amino acids (Fig 5, S3 Table) . Aromatic residues F1713 and Y1728, relevant for stacking interaction with the m 7 GTP in the structure (Fig 2B and 2C) , could be changed to other aromatic amino acids (F, Y, W) without loss in transcriptional activity, even though they are almost completely conserved among phlebo-and banyangviruses (Fig 3) . Mutation of those aromatic residues to chemically different amino acids resulted either in a complete loss of L protein activity (F1713) or a selective defect in viral transcription (Y1728, Fig 5 , columns of mutants with selective transcription defect are colored in red). Substitution of R1716 by chemically different amino acids also resulted in a selective transcription defect, which is somehow surprising considering the low degree of conservation among phlebo-and banyangviruses (Fig 3) . A selective defect in viral transcription was also caused by mutations of residues Q1717 and N1749, although this effect was not observed for all substitutions. Residue M1782 could not be exchanged for other amino acids without a strong negative effect on general L protein function. We also included residue W1778 in our mutational study, because this is the only fairly conserved aromatic residue located in the α-helix, although it is not part of the cap-binding site ( Fig 2C) . W1778 is obviously of importance for general L protein function as mutations to non-aromatic amino acids resulted in a complete loss of L protein activity, whereas the exchange for a phenylalanine had no effect.
In summary, changes of the chemical properties of side chains directly interacting with m 7 GTP in the RVFV CBD structure mostly result in selective transcription defects in the context of the full-length L protein. These results support our structural data and underline the importance of the identified m 
Overall structural comparison of RVFV CBD with related domains of other negative strand RNA viruses
The overall structure of RVFV CBD is similar to the known structures of influenza A virus PB2 cap-binding domain [29] and CASV putative cap-binding domain [21] (Fig 6B) . . Among other criteria, mutants with a selective defect in viral transcription are expected to show signals below 55% of wild-type activity (range is indicated by grey background). Synthesis of the antigenome and Ren-Luc mRNA was evaluated by northern blotting using a radiolabelled antisense riboprobe hybridizing to the Ren-Luc gene. A defective L protein with a mutation in the catalytic site of the RNA-dependent RNA polymerase served as a negative control (neg.). Signals on northern blots were quantified using ImageJ2 software [58] . All lanes displayed are from the same northern blot membrane (and same autoradiogram), dotted lines indicate cutting of the lanes for presentation reasons. The original blot is presented in S9 Table. B) The column chart displays the signal ratio of mRNA to antigenome, reflecting viral transcription vs. replication, relative to the wild-type as calculated from the quantified northern blot signals. The expected range of signal ratio for mutants with a selective Topology diagrams in Fig 6C provide an overview of the structural compositions of these proteins. They all consist of a large β-sheet packed against a long α-helix (α 1 ). The β-hairpin present in the PB2 and RVFV CBD structures (β H1+2 ) is replaced by a long loop in the CASV structure. This β-hairpin is much longer in the PB2 structure compared to the RVFV structure. The large β-sheet is very twisted in PB2 and consists of 8 β-strands whereas it is quite straight and only composed of 5 β-strands in the CASV structure. RVFV CBD contains a moderately twisted 7-stranded β-sheet and is thus structurally an intermediate between CASV and PB2 structures. The PB2 cap-binding domain is larger than CASV putative cap-binding domain and RVFV CBD. The structural similarity between those three protein domains is striking, considering the low degree of sequence conservation (S6 and S7 Figs).
Comparison of the RVFV cap-binding site residues with related proven or putative cap-binding sites
In many cap-binding proteins like eukaryotic initiation factor 4E (eIF4E), cellular cap-binding complex (CBC) or influenza virus PB2, the cap structures are bound between two aromatic side chains [25, 29] . This is also true for RVFV CBD. However, in the PB2 structure the two residues that bind the guanine moiety of the cap are located in the β-hairpin (H357 in β H2 ) and at the end of the long α-helix (F404 in α 1 ), respectively (Fig 6B, right panel) . Additionally, the ribose interacts with a phenylalanine side chain (F323 in β 1 ) extending from the first β-strand of the large β-sheet (Fig 6B, right panel, S5C Fig) . In RVFV CBD, no aromatic amino acid is present at the end of the long α-helix (α 1 ). Instead, the guanine moiety is bound between two aromatic side chains extending from the β-hairpin (Y1728 in β H2 ) and the first β-strand (F1713 in β 1 ) (Fig 6B, middle panel, Fig 2C, S5B Fig) , which are also highly conserved among phlebo-and banyangviruses (Fig 3) . The latter residue, F1713, corresponds to F323 of influenza virus PB2, which in PB2 interacts with the ribose. In RVFV CBD methionine 1782 at the end of the long α-helix (α 1 ) takes the role of positioning the ribose (Fig 2C, S8 Fig) . In case of the CASV C-terminal domain, there is a conserved aromatic residue (Y1872 in α 1 ) located at the end of the long α-helix, similar to F404 in influenza virus PB2, but no second residue in a conformation and distance suitable for a stacking interaction with a cap-structure is present (Fig 6B, left panel) . Among phlebo-and banyangviruses, we found only one aromatic residue near the end of the long α-helix (α 1 ), W1818, which is conserved in about 85% of the analyzed sequences (Fig 3) . The tryptophan side chain, however, would be unable to interact with m 7 GTP in our structure as it is covered by M1782 (Fig 2C) . In summary, although the tertiary structure of the (putative) cap-binding domains of influenza virus, CASV, and RVFV is highly conserved, the atomic details of the cap binding sites differ significantly.
Discussion
Cap-snatching was first discovered in influenza virus [30] and is an attractive drug target, because the process is essential for virus amplification and the enzymes involved are virus encoded. This mechanism comprises two targets: the endonuclease and the cap-binding site. However, whereas several structures of bunyavirus endonucleases have been solved and the enzyme has been characterized relatively well [7, 16, [18] [19] [20] [21] 31] , structural data on the capdefect in mRNA production is indicated by grey background (� 0.25). Columns of mutants with a selective defect in viral transcription are colored in red. C) This column chart shows the antigenome levels determined by northern blot quantification relative to the wild-type level. L protein mutants with a selective transcription defect are expected to show wild-type like antigenome levels (� 40%, indicated by grey background). Columns of mutants with a selective defect in viral transcription are colored in red.
https://doi.org/10.1371/journal.ppat.1007829.g005
The cap-binding domain of Rift Valley fever virus L protein The cap-binding domain of Rift Valley fever virus L protein binding site of bunyaviruses is rare and functional data is missing. The publication of the structure of a reptarenavirus L protein domain structurally similar to influenza virus PB2, but deficient of cap-binding activity raised the question whether the observed inability of capbinding truly reflects the situation in mammarenaviruses and possibly all viruses of the Bunyavirales order [21] .
Here we present the structure of a small globular domain located in the C-terminal region of RVFV L protein along with the first evidence for a functional cap-binding site within the bunyavirus L protein. The new structure is similar to influenza virus PB2 cap-binding domain and CASV putative cap-binding domain. The RVFV protein specifically binds to a cap-analogue in vitro and upon co-crystallization the cap-analogue could be detected bound between two aromatic side chains, as it is typical for several cellular and viral cap-binding proteins [25] . Still, the residues involved in the interactions with the ligand differ significantly between influenza virus PB2 and RVFV cap-binding domain. These findings pose the following questions: (1) Is a functional cap-binding domain a common feature of all viruses within the Bunyavirales order? (2) Will it be possible to design broad-spectrum inhibitors targeting the cap-binding domain of segmented negative sense RNA viruses despite the observed differences in the binding mode of m 7 
GTP?
The presented data support the hypothesis that bunyavirus L proteins are functionally and structurally equivalent to the concatenation of influenza virus polymerase subunits in the order PA-PB1-PB2 [17] . The presence of a β-hairpin in the RVFV structure, similar to PB2 but different from the CASV structure, suggests that the new structure might be more closely related to influenza virus cap-binding domain from an evolutionary perspective, which is contrary to what is described in the literature [32] , although it is worth mentioning that most of the phylogenetic analyses for the L gene are based on the conserved RNA-dependent RNA polymerase region. The evolutionary relation of the cap-binding domains will be difficult to prove, as the observed similarity is not obvious from the sequence level (S6 and S7 Figs).
Our data illustrate the structural flexibility of proteins with the same function, even though they are evolutionarily closely related. This is probably the reason why it is unlikely to reliably predict the cap-binding site in L proteins of different families within the Bunyavirales order from the sequence level. The C-terminal part of the L protein of Bunyavirales is poorly conserved, making sequence alignments challenging. Furthermore, the location of the proven or putative cap-binding domain within the polymerase proteins differs between RVFV, CASV and influenza virus, which makes a correct alignment of these sequences even more difficult. Whereas for CASV the putative cap-binding domain is between 250 and 150 amino acids distance from the C-terminus, for RVFV this domain is between 390 and 270 residues away from the C-terminus (Fig 6A) . The evolutionary context of this observation will be interesting to investigate in the future. We created an alignment of the proven and putative cap-binding domains of phlebo-and closely related banyangviruses, as well as arenaviruses and influenza A virus based on the observed structural similarities ( S6 Fig). This alignment has to be interpreted with caution, as it demonstrates the very low degree of sequence conservation in this domain (see identity/ similarity matrix in S7 Fig) . The lack of a reasonable alignment makes it highly unlikely to model the cap-binding domains of other bunyaviruses based on the known structures. This underlines the need to localize and solve structures of further putative capbinding domains in order to fully understand the cap-snatching mechanism of bunyaviruses.
For the development of potentially broad-spectrum inhibitors against viruses from the Bunyavirales order as well as influenza viruses, the structures of the cap-binding cavities are essential. The binding site topology of the RVFV L protein cap-binding domain, however, is different from the PB2 cap-binding site: The corresponding essential aromatic residue from the end of the long α-helix (α 1 ) in PB2 (F404) is absent in the RVFV structure. Instead, this function is taken over by an aromatic residue (F1713) located in the first β-strand (β 1 ) of the sheet. The equivalent residue in influenza virus PB2 (F323) is responsible for stacking the ribose moiety of the cap ( S8 Fig). Interestingly, the aromatic residue at the end of the long α-helix (α 1 ) is present in the CASV domain (Y1872), although no reasonable candidate as a second partner for an aromatic sandwich is apparent (Fig 6B, S8 Fig) .
We were able to demonstrate binding of the RVFV CBD to m 7 GTP, a cap-analogue. In a thermal stability assay we observed stabilization of RVFV CBD by m 7 GTP. Additionally, we determined the K D of the low affinity interaction between m 7 GTP and RVFV CBD, which was considerably high with 737 μM. For influenza A virus PB2, both the shift in melting temperature in presence of m 7 GTP (ΔT m <9˚C, Fig 4) and the K D for interaction with m 7 GTP, which was shown to be~1.5 μM in vitro [26] , point to a higher affinity interaction with the m 7 GTP compared to RVFV cap-binding domain. This difference is not surprising, considering the few interactions observed between the RVFV L protein fragment and the ligand in the structure (compare S5B and S5C Fig, S2 Table) and the fact that we are working with an isolated L protein domain. The affinity of RVFV full-length L protein for capped mRNAs has to be much higher to compete for the ligand with other cap-binding proteins inside the cytoplasm. The K D for the interaction of human eIF4E with m 7 GTP is~0.87 μM [33] . This suggests that there have to be more residues in RVFV L protein interacting with the cap-structure or the first nucleotides of the capped mRNA apart from the small domain presented here. This is conceivable as for influenza virus PB2 residues of the cap-binding adjacent, so-called mid-link domain have been shown to interact with the capped RNA [34] . Alternatively, other mechanisms may support RVFV cap-binding activity. As an example, arenavirus Z protein has been shown to interact with eIF4E and to down-regulate its affinity for cap-structures [35] . Although most bunyaviruses do not contain a Z gene, similar scenarios involving viral proteins are conceivable. Furthermore, bunyavirus non-structural proteins have been shown to regulate host transcription and replication [36] . Additionally, cellular interaction partners of the L protein might play a role in the cap-snatching process as well as the cellular localization of viral transcription processes.
For influenza virus several compounds targeting the two functions involved in cap-snatching, the endonuclease and cap-binding site, have been reported over the past years [37] [38] [39] [40] [41] , two of those having succeeded in clinical trials [42, 43] . An inhibitor of influenza endonuclease has been shown to be also effective against the homologous enzyme of La Crosse bunyavirus in vitro [44] , which demonstrates the possibility to develop broad-spectrum inhibitors against the cap-cleaving endonucleases of influenza viruses and bunyaviruses. However, the observed differences in the topology of the cap-binding sites of influenza virus and RVFV are likely to be a challenge for the design of broad-spectrum inhibitors targeting cap-binding. Further structures of Bunyavirales cap-binding domains are essential to evaluate this option. The structural and functional data presented here, provide evidence for the existence of a functional capbinding domain in bunyavirus L protein essential for viral transcription as well as the foundation for structure based drug development against RVFV cap-snatching mechanism.
Materials and methods
Cloning, expression and purification of RVFV L protein C-terminus
Based on an alignment of phlebo-and banyangvirus L protein C-terminal sequences, we designed constructs for RVFV L protein (strain ZH-501, Uniprot accession: A2SZS6) covering the area between residues 1677 and 2008. All sequences were cloned into pOPINF vectors [45] using the NEBuilder HiFi DNA Assembly Cloning Kit (New England BioLabs). Proteins were expressed in E. coli strain BL21 Gold (DE3) (Novagen) at 17˚C overnight using TB medium and 0.5 mM isopropyl-β-D-thiogalactopyranosid for induction. After pelleting, the cells were resuspended in 50 mM Na-phosphate pH 7.5, 100 mM NaCl, 10 mM imidazole, Complete protease inhibitor EDTA-free (Roche), 0.4% (v/v) triton X-100 and 0.025% (w/v) lysozyme and subsequently disrupted by sonication. The protein was purified from the soluble fraction after centrifugation by Ni affinity chromatography. Buffers containing either 50 mM imidazole and 1 M NaCl or 50 mM imidazole and 100 mM NaCl were used for the washing steps and another buffer with 500 mM imidazole for the elution of the protein. Eluted protein was immediately diluted with 20 mM Na-phosphate pH 6.5 followed by removal of the N-terminal His-tag by a GST-tagged 3C protease at 4˚C overnight. The protein was further purified by passing through an anion exchange chromatography column (HiTrap Q FF, GE Healthcare) and subsequent cation exchange chromatography (Hi Trap SP FF, GE Healthcare, loading buffer: 50 mM Na-phosphate pH 6.5, 50 mM NaCl, 10% (w/v) glycerol, elution with salt gradient up to 1M NaCl). After addition of up to 3 mM m 7 GTP the protein was concentrated for a final size exclusion chromatography (Superdex 200, 50 mM Na-phosphate, pH 6.5, 150 mM NaCl, 10% (w/v) glycerol). Purified proteins were concentrated using centrifugal devices with addition of up to 6 mM m 7 GTP (final concentration), flash frozen in liquid nitrogen, and stored in aliquots at -80˚C. For thermal stability assays and isothermal titration calorimetry purification procedure was done without addition of m 7 GTP resulting in lower protein concentrations of max. 4.5 mg/ml.
Production of seleno-methionine labelled protein
Protein expression was done in M9 minimal medium [46] supplemented with 1 mM MgSO 4 , 0.4% glucose, 0.0005% thiamine and 200 μM FeSO 4 at 17˚C overnight. Incorporation of seleno-methionine was achieved by metabolic inhibition of methionine biosynthesis in E. coli prior to addition of seleno-methionine and induction with 1 mM isopropyl-β-D-thiogalactopyranosid. Cells were harvested and the labelled protein was purified as described but in presence of 5 mM β-mercaptoethanol for Ni affinity purification and 10 mM DTT for the remaining purification steps.
Crystallization and structure determination RVFV CBD13 protein was produced with seleno-methionine labelling, CBD9 only as native protein. Protein crystals of CBD9 grew at 8 mg/ml protein concentration in 21% PEG 4000, 10% glycerol, 12% isopropanol and 100 mM Na-Citrate pH 6.0 in a sitting drop vapor diffusion setup at 20˚C. Protein crystals of CBD13 grew at 9 mg/ml protein concentration in 24% PEG 2000 MME, 200 mM Trimethylamine N-oxide, 2 mM TCEP, 5 mM dithiothreitol, 2 mM m 7 GTP and 100 mM Tris, pH 8.5 in a sitting drop vapor diffusion setup at 20˚C. Crystals were flash frozen in liquid nitrogen without cryo protectants in case of CBD13 and with 25% ethylenglycol in reservoir solution for CBD9. Datasets were obtained at beamline P13 of PETRA III at Deutsches Elektronen Synchrotron (DESY), Hamburg, Germany. Datasets were processed with iMosflm [47] and the RVFV CBD13 structure was solved by the single anomalous dispersion method using PHENIX AutoSol [48] . The structure was refined by iterative cycles of manual model building in Coot [49] and computational optimization with PHENIX [48] . Visualization of structural data was done using the PyMOL Molecular Graphics System, Version 1.7 Schrödinger, LLC.
Thermal stability assay
Thermal stability of RVFV CBD13 was measured by thermofluor assay [50] . The assay contained a final concentration of 15 μM of CBD13 protein, 20 mM Na-phosphate pH 6.5, 100 GTP in the syringe at 25˚C with 19 injections of 2 μl (first injection 0.5 μl), or (3) 194 μM CBD13 in the cell and 9.8 mM GTP in the syringe at 25˚C with 19 injections of 2 μl (first injection 0.5 μl). Spacing between injections was constant with 150 seconds for all measurements. Data were analyzed and fitted with the respective PEAQ ITC evaluation software (Malvern) applying a single site binding model and fixing the stoichiometry value to 1.
Testing of L protein mutants in the RVFV minireplicon system
The experiments were performed in the context of the T7 RNA polymerase-based RVFV ambisense minireplicon system essentially as described by Jérôme et al. [23] . L gene mutants were generated by mutagenic PCR using pCITE-L as a template. The PCR products containing the functional cassette for expression of mutant L protein were purified, quantified spectrophotometrically, and used for transfection without prior cloning. The presence of the artificial mutation was ascertained by sequencing. BSR-T7/5 cells stably expressing T7 RNA polymerase [51] (kindly provided by Ursula Buchholz and Karl-Klaus Conzelmann) were transfected per well of a 24-well plate with 250 ng of L gene PCR product, 750 ng of RVFV minigenome plasmid expressing Renilla luciferase (Ren-Luc), 500 ng of pCITE-NP expressing NP, and 10 ng of pCITE-FF-Luc expressing firefly luciferase as an internal transfection control. One day after transfection, total RNA was purified using an RNeasy Mini Kit (Qiagen) for northern blotting or cells were lysed in 100 μl of passive lysis buffer (Promega) per well, and assayed for firefly luciferase and Ren-Luc activity using the dual-luciferase reporter assay system (Promega). Ren-Luc levels were corrected with the firefly luciferase levels (resulting in standardized relative light units [sRLU]) to compensate for differences in transfection efficiency or cell density.
For northern blot analysis, 500 ng of RNA was separated in a 1.5%-agarose-formaldehyde gel and transferred onto a Roti-Nylon plus membrane (Roth). Blots were hybridized with a 32 P-labelled antisense riboprobe targeting the Ren-Luc gene, and RNA bands were visualized by autoradiography using a Typhoon scanner (GE Healthcare).
To verify expression of L protein mutants, BSR-T7/5 cells in a well of a 24-well were transfected with 500 ng of PCR product expressing L protein mutants tagged at the C-terminus with a 3xFLAG sequence. To enhance the expression level, the cells were additionally inoculated with Modified Vaccinia virus Ankara expressing T7 RNA polymerase (MVA-T7) [52] . Cytoplasmic lysate was separated in a 3-8% Tris-acetate polyacrylamide gel, transferred to nitrocellulose membrane (Whatman), and detected by immunoblotting using peroxidase-conjugated anti-FLAG M2 antibody (1:10,000) (A8592; Sigma-Aldrich). L protein bands were visualized by chemiluminescence using SuperSignal West Femto substrate (Pierce) and a FUSION SL image acquisition system (Vilber Lourmat). This figure presents an alignment of the (putative) cap-binding domains of 2 reptarenaviruses (light green label), 4 mammarenaviruses (dark green label), 7 phleboviruses and 1 banyangvirus (blue label) and influenza A virus (red label). The alignment was essentially based on predicted secondary structures and calculated using PRALINE software [53, 56] but required major manual adjustments. Graphical presentation of the alignment was done using ESPript (http://espript.ibcp.fr) [57] . The secondary structure of RVFV CBD (PDB 6QHG, on blue background) and influenza virus cap-binding domain (PDB 2VQZ, on red background) are displayed above and below the sequences, respectively. Secondary structure elements are labelled according to 
